Opinion statement
Chemotherapy remains the key treatment for small cell lung cancer; today, that chemotherapy remains cisplatin and etoposide in a variety of acceptable schedules. Attempts to use new drugs in extensive disease have not been as successful as hoped; however, a recent trial from Japan supports the use of irinotecan and cisplatin over the standard cisplatin and etoposide, but these facts need to be verified in western countries. For limited disease, the addition of thoracic radiotherapy for all patients and prophylactic cranial irradiation (PCI) in complete, or near complete, responders have resulted in improved survival. The best results occur with early, intensive thoracic radiotherapy concurrent with chemotherapy and PCI after completion of systemic and local therapy. The use of PCI and thoracic radiotherapy in extensive disease is more controversial and less evidence based. PCI and thoracic radiotherapy may be considered only in patients who have achieved a “systemic” complete response and excellent response in the chest. However, both prospects should be supported if there is complete response systemically and near complete response locally. The role of surgery is of limited value in the unusual cases of mediastinal negative disease, but it is a good treatment for patients with peripheral nodules and sufficient pulmonary function to withstand thoracotomy.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Page NC, Read WL, Tierney RM, et al.: The epidemiology of small cell lung carcinoma [abstract]? Proc Am Soc Clin Oncol 2002, 21:305a.
Ettinger DS, Seiferheld WF, Abrams RA, et al.: Cisplatin (P), etoposide (E), paclitaxel (T) and concurrent hyperfractionated thoracic radiotherapy (TRT) for patients with limited disease (LD) small cell lung cancer (SCLC): preliminary results of RTOG 95-09 [abstract]? Proc Am Soc Clin Oncol 2000, 19:490a.
Niell H, Herndon JE, Miller AA, et al.: Randomized phase III intergroup trial (CALGB 9732) of etoposide (VP-16) and cisplatin (DDP) with or without paclitaxel (TAX) and G-CSF in patients with extensive small cell lung cancer (ED-SCLC) [abstract]? Proc Am Soc Clin Oncol 2002, 21:293a.
Kosmidis PA, Samanta E, Fountzilas G, et al.: Cisplatin/ etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Hellenic Cooperative Group for Lung Cancer Trials? Semin Oncol 1994, 21(Suppl 3):23–30. Kosmidis et al. report that 300 mg/m2 of carboplatinum is an equivalent to cisplatin given 50 mg/m2 on days 1 and 2. However, this trial is not powered to establish equivalence.
Work E, Nielsen OS, Bentzen SM, et al.: Randomized study of initial versus late chest irradiation combined with chemotherapy in limited small-cell lung cancer? J Clin Oncol 1997, 15:3030–3037.
Takada M, Fukuoka M, Kawahara M, et al.: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited small cell lung cancer? J Clin Oncol 2002, 20:3054–3060.
Turrisi AT, Kim K, Blum R, et al.: Twice daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin etoposide? N Engl J Med 1999, 340:265–271. The US intergroup study provides proof of principle that intensive radiotherapy improves survival of patients with limited disease. Once-daily schedules of higher dose are used widely, but are not supported by evidence.
Auperin A, Arriagada R, Pignon JP, et al.: Prophylactic cranial irradiation for patients with small cell lung cancer in complete remission? N Engl J Med 1999, 341:476–484. This is the meta-analysis that proves a survival benefit of approximately 5% for patients treated with prophylactic cranial irradiation. Most of the studies predated current chemotherapy and radiotherapy schedules.
Jeremic B, Shibamoto Y, Nikolic N, et al.: Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study? J Clin Oncol 1999, 17:2092–2099.
Shepherd F: Surgical management of small-cell lung cancer. In Lung Cancer: Principles and Practice. Edited by Pass HI, Mitchell JB, Johnson DH, et al. Philadelphia: Lippincott Williams & Wilkins; 2000:967–980.
Eberhardt W, Stamatis G, Stuschke M, et al.: Prognostically oriented multimodality treatment including surgery for selected patients of small-cell lung cancer patients stages IB to IIIB: long-term results of a phase II trial? Br J Cancer 1999, 81:1206–1212.
Noda K, Nishiwaki Y, Kawahara M, et al.: Irinotecan plus cisplatin for extensive small-cell lung cancer? N Engl J Med 2002, 346:85–91. This is the Japanese report touting a survival advantage for patients treated with the every-4-week irinotecan/platinum regimen over the every-3-week platinum etoposide regimen.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Turrisi, A.T. Limited stage small cell lung cancer: Treatment and therapy. Curr. Treat. Options in Oncol. 4, 61–64 (2003). https://doi.org/10.1007/s11864-003-0032-9
Issue Date:
DOI: https://doi.org/10.1007/s11864-003-0032-9